Role of newer medications for bipolar disorder.

Abstract:

:The quest for additional effective therapies for bipolar study commenced in the 1960s, even before regulatory approval of lithium. This was driven by the recognition that patient response to lithium varied from excellent to poor; thus, significant numbers of patients faced its frequent adverse effects and risks without sustaining any benefit. These needed advances have been slowed by the unusual difficulties of studying bipolar disorder in controlled, rigorously designed protocols. These difficulties are reviewed both from the perspective of their effects on research and on clinical practice. In addition, the results of two blinded, placebo-controlled studies of divalproex in the treatment of acute mania are compared with results from earlier open and comparator studies. The comparisons indicate that open-study results with divalproex and other forms of valproic acid have yielded results quite similar to those observed under rigorous study conditions. Whereas substantial evidence exists regarding the efficacy of divalproex and carbamazepine and their roles in treating patients with bipolar disorder, studies evaluating other putative mood-stabilizing agents and antidepressants in bipolar disorder are few in number and inconsistent in results. With few exceptions, studies of these latter drugs do not provide clear guidelines for treatment.

journal_name

J Clin Psychopharmacol

authors

Bowden CL

doi

10.1097/00004714-199604001-00006

subject

Has Abstract

pub_date

1996-04-01 00:00:00

pages

48S-55S

issue

2 Suppl 1

eissn

0271-0749

issn

1533-712X

journal_volume

16

pub_type

杂志文章,评审
  • Treatment of negative schizophrenic symptoms with alprazolam: a preliminary open-label study.

    abstract::Eight schizophrenic patients received alprazolam in an open-label protocol. A partial reversal of negative symptoms was noted in six of the eight patients. Also, all eight experienced a decrease in anxiety. Alprazolam in doses of 5 to 7 mg/day yielded steady state plasma levels of 6 to 64 ng/ml. As the drug was well t...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Csernansky JG,Lombrozo L,Gulevich GD,Hollister LE

    更新日期:1984-12-01 00:00:00

  • Trends in the adoption of medications for alcohol dependence.

    abstract::Increasing attention is being paid to the development and dissemination of effective pharmacotherapies for the treatment of alcohol and other drug dependence. However, numerous structural and philosophical barriers impede the widespread adoption of these treatment approaches in everyday clinical practice. Research is ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1097/01.jcp.0000246209.18777.14

    authors: Ducharme LJ,Knudsen HK,Roman PM

    更新日期:2006-12-01 00:00:00

  • Efficacy of Desvenlafaxine Compared With Placebo in Major Depressive Disorder Patients by Age Group and Severity of Depression at Baseline.

    abstract:PURPOSE:This post hoc meta-analysis evaluated the efficacy and safety of desvenlafaxine 50 and 100 mg versus placebo across age groups and severity of depression at baseline in patients with major depressive disorder. METHODS:Data from placebo and desvenlafaxine 50-mg and 100-mg dose arms were pooled from 9 short-term...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,meta分析

    doi:10.1097/JCP.0000000000000674

    authors: Mosca D,Zhang M,Prieto R,Boucher M

    更新日期:2017-04-01 00:00:00

  • Double-blind, placebo-controlled study of single-dose metergoline in depressed patients with seasonal affective disorder.

    abstract::A role for serotonin in season affective disorder (SAD) has been explored with a variety of serotonergic pharmacologic agents. The authors initially hypothesized that metergoline, a nonspecific serotonin antagonist, would exacerbate depressive symptoms. In a small, open-label pilot study, the authors observed the oppo...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-200204000-00018

    authors: Turner EH,Schwartz PJ,Lowe CH,Nawab SS,Feldman-Naim S,Drake CL,Myers FS,Barnett RL,Rosenthal NE

    更新日期:2002-04-01 00:00:00

  • Methamphetamine self-administration in humans during D-amphetamine maintenance.

    abstract::Agonist replacement may be a viable treatment approach for managing stimulant use disorders. This study sought to determine the effects of D-amphetamine maintenance on methamphetamine self-administration in stimulant using human participants. We predicted that D-amphetamine maintenance would reduce methamphetamine sel...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000207

    authors: Pike E,Stoops WW,Hays LR,Glaser PE,Rush CR

    更新日期:2014-12-01 00:00:00

  • Concentration-response relationship for fluvoxamine using remission as an endpoint: a receiver operating characteristics curve analysis in major depression.

    abstract::Therapeutic drug monitoring studies of selective serotonin reuptake inhibitor (SSRI) antidepressants thus far failed to identify a clear concentration-response relationship in major depression. Majority of the previous studies defined clinical response as 50% or greater reduction from baseline in depression rating sca...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0b013e3181730850

    authors: Suzuki Y,Fukui N,Sawamura K,Sugai T,Watanabe J,Ono S,Inoue Y,Ozdemir V,Someya T

    更新日期:2008-06-01 00:00:00

  • Amoxapine versus amitriptyline for continuation therapy of depression.

    abstract::The efficacy of continuation therapy with tricyclic antidepressants has been established in a number of controlled trials. This study investigated the efficacy of continuation therapy with a relatively new antidepressant, amoxapine, using a double-blind controlled comparison with amitriptyline. Subjects met DSM-III cr...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Mason BJ,Kocsis JH,Frances AJ,Mann JJ

    更新日期:1990-10-01 00:00:00

  • The clinical use of anticholinergic drugs as treatment for extrapyramidal side effects of neuroleptic drugs.

    abstract::The clinician using neuroleptic drugs for the treatment of psychotic patients must face a number of questions regarding whether and how to use anticholinergic drugs when extrapyramidal side effects appear. This article explores some of these questions, suggests how they might best be answered, reviews the studies whic...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: McEvoy JP

    更新日期:1983-10-01 00:00:00

  • Alprazolam treatment of postcoronary bypass anxiety and depression.

    abstract::The effectiveness of alprazolam in treating symptoms of anxiety and depression in 60 patients undergoing coronary bypass surgery was assessed in a double-blind, placebo-controlled study. The results indicate that alprazolam treatment for anxiety following coronary bypass surgery, particularly symptoms occurring in the...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Freeman AM 3rd,Fleece L,Folks DG,Sokol RS,Hall KR,Pacifico AD,McGiffin DC,Kirklin JK,Zorn GL,Karp RB

    更新日期:1986-02-01 00:00:00

  • Efficacy and safety of venlafaxine in the treatment of bipolar II major depressive episode.

    abstract::As many as 45% of patients with major depression also meet diagnostic criteria for bipolar (BP) II disorder. Although the use of a concurrent mood-stabilizing drug has been suggested in treating BP II depression, antidepressant monotherapy has received less attention. The efficacy and safety of venlafaxine were examin...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-199810000-00010

    authors: Amsterdam J

    更新日期:1998-10-01 00:00:00

  • Prolactin and Estrogen Levels in Postmenopausal Women Receiving Aripiprazole Augmentation Treatment for Depression.

    abstract:BACKGROUND:Antipsychotic drugs are well established to alter serum prolactin levels, often resulting in adverse effects including amenorrhea, galactorrhea, osteoporosis, and loss of libido. There is growing preclinical evidence that prolactin-elevating drugs can instigate the progression of precancerous lesions to brea...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000001335

    authors: Rahman T,Patrick C,Ma C,Nicol GE,Reynolds CF 3rd,Mulsant BH,Hartz SM,Yingling M,Lenze EJ

    更新日期:2021-01-01 00:00:00

  • Blood levels of haloperidol and thioridazine during maintenance neuroleptic treatment of schizophrenic outpatients.

    abstract::Plasma and red blood cell levels of haloperidol, thioridazine, and thioridazine's main metabolite mesoridazine were measured in schizophrenic outpatients during treatment with fixed doses of haloperidol or thioridazine for several months. These drug levels were compared to those in schizophrenic inpatients treated wit...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Shvartsburd A,Sajadi C,Morton V,Mirabi M,Gordon J,Smith RC

    更新日期:1984-08-01 00:00:00

  • Dose-related effects of estazolam on sleep of patients with insomnia.

    abstract::The dose range of estazolam for hypnotic effects was studied in seven men and eight women (mean age 30.3 +/- 8.6 years) who complained of insomnia and had polysomnographic evidence of disturbed sleep. Patients slept in the laboratory and were monitored using standard polysomnographic techniques. Four consecutive night...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Roehrs T,Zorick F,Lord N,Koshorek GL,Roth T

    更新日期:1983-06-01 00:00:00

  • Lack of pharmacologic interaction between paroxetine and alprazolam at steady state in healthy volunteers.

    abstract::This investigation aimed to provide evidence on the lack of pharmacokinetic interaction of paroxetine (20 mg/d) and alprazolam (1 mg/d) in combined therapy. In addition, the central effects of both drugs when administered alone and in combination were assessed to rule out any relevant synergistic depressant central ef...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/01.jcp.0000125689.05091.c6

    authors: Calvo G,García-Gea C,Luque A,Morte A,Dal-Ré R,Barbanoj M

    更新日期:2004-06-01 00:00:00

  • Aripiprazole in schizophrenia with cocaine dependence: a pilot study.

    abstract::The debilitation of schizophrenia (SCHZ) worsens markedly with comorbid cocaine dependence (CD) and alcohol abuse. To date, no medications have conclusively demonstrated effects against both SCHZ and CD (SCHZ + CD) simultaneously. Because of its dopamine-modulating properties, we hypothesized that aripiprazole would a...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/01.jcp.0000169419.38899.5b

    authors: Beresford TP,Clapp L,Martin B,Wiberg JL,Alfers J,Beresford HF

    更新日期:2005-08-01 00:00:00

  • Risperidone-related weight gain: genetic and nongenetic predictors.

    abstract:OBJECTIVE:A serious side effect of atypical antipsychotics is increased body weight, which leads to further morbidity and nonadherence to medication. It has been suggested that both genetic and nongenetic variables may influence antipsychotics-related weight gain. This study aimed to simultaneously explore the effects ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/01.jcp.0000203196.65710.2b

    authors: Lane HY,Liu YC,Huang CL,Chang YC,Wu PL,Lu CT,Chang WH

    更新日期:2006-04-01 00:00:00

  • International Study of Expert Judgement on Therapeutic Use of Benzodiazepines and Other Psychotherapeutic Medications: V. Treatment strategies in panic disorder, 1992-1997.

    abstract::The objective of this study was to assemble expert clinical experience and judgment regarding the treatment of panic disorder in a systematic, quantitative manner, particularly with respect to changes during the past 5 years. A panel of 73 internationally recognized experts in the field of pharmacotherapy of anxiety a...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004714-199812001-00006

    authors: Uhlenhuth EH,Balter MB,Ban TA,Yang K

    更新日期:1998-12-01 00:00:00

  • The pharmacologic treatment of neuroleptic-induced akathisia.

    abstract::Akathisia is a frequent and distressing side effect of neuroleptic medications. The literature regarding the pharmacologic treatment of acute neuroleptic-induced akathisia is critically reviewed, including nine reports of the use of anticholinergic agents, 15 of the use of beta-blocking agents, and six of the use of b...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,评审

    doi:10.1097/00004714-199002000-00003

    authors: Fleischhacker WW,Roth SD,Kane JM

    更新日期:1990-02-01 00:00:00

  • Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study.

    abstract::This 12-week, double-blind, multicenter trial evaluated the efficacy of venlafaxine extended release (ER), sertraline, and placebo in adult outpatients (N = 538) with a primary diagnosis of posttraumatic stress disorder (PTSD), as defined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, sy...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/01.jcp.0000222514.71390.c1

    authors: Davidson J,Rothbaum BO,Tucker P,Asnis G,Benattia I,Musgnung JJ

    更新日期:2006-06-01 00:00:00

  • Effects of third trimester fluoxetine exposure on the newborn.

    abstract::Prospectively identified fluoxetine-exposed pregnancies were evaluated to determine whether fluoxetine, a serotonin reuptake inhibitor commonly used for the treatment of depression and obsessive-compulsive disorder, might be associated with neonatal complications after maternal fluoxetine exposure during the third tri...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004714-199512000-00005

    authors: Goldstein DJ

    更新日期:1995-12-01 00:00:00

  • Quantitative electroencephalogram examination of effects of risperidone in schizophrenic patients.

    abstract::The objective of this study was twofold: (1) to describe the effects of risperidone on the quantitative electroencephalogram (EEG) in schizophrenic patients and (2) to explore the relationships between EEG changes and clinical improvement. The subjects were nine male schizophrenic patients participating in a placebo-c...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Czobor P,Volavka J

    更新日期:1993-10-01 00:00:00

  • Substance-induced dissociative disorders and psychiatric nosology.

    abstract::Transient amnesias, fugues, twilight states, automatisms, depersonalization, and furors or explosive disorders can occur in association with, or be caused by, various medications or substance-induced organic brain states. Agents capable of precipitating dissociative-like states include alcohol, barbiturates and simila...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Good MI

    更新日期:1989-04-01 00:00:00

  • Risperidone But Not Quetiapine Treatment Is Associated With Increased Appetite But Not Satiety Hormones in Children During An Oral Glucose Tolerance Test: A Pilot Study.

    abstract:BACKGROUND:Second-generation antipsychotics (SGAs) are commonly used to treat children with mental health conditions (MHCs) but are associated with adverse effects including obesity, hypertension, dyslipidemia, and type 2 diabetes. The mechanisms underlying these complications are unknown, but it has been suggested tha...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000956

    authors: Ngai YF,Devlin AM,Panagiotopoulos C

    更新日期:2018-12-01 00:00:00

  • Clozapine reduces water-drinking behavior in schizophrenic patients with polydipsia.

    abstract::Disordered water balance, or polydipsia, is an underassessed and underreported phenomenon present in the severely psychiatrically disabled population. Prevalence rates for polydipsia range from 6.2 to 20%. We followed up five male patients (mean age 43) with chronic schizophrenia who met the Kane criteria for being tr...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004714-199608000-00010

    authors: Fuller MA,Jurjus G,Kwon K,Konicki PE,Jaskiw GE

    更新日期:1996-08-01 00:00:00

  • Open-label pilot study of modafinil for methamphetamine dependence.

    abstract::Methamphetamine has become a major public health issue globally, particularly in the United States. Despite this, no effective pharmacotherapy for methamphetamine abuse has been developed to date. This 6-week, open-label pilot clinical trial examined the safety and tolerability of modafinil up to 400 mg/d in 8 methamp...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/JCP.0b013e3181b591e0

    authors: McGaugh J,Mancino MJ,Feldman Z,Chopra MP,Gentry WB,Cargile C,Oliveto A

    更新日期:2009-10-01 00:00:00

  • Mianserin pharmacokinetics and behavior in hyperkinetic children.

    abstract::The present study was conducted to derive pediatric mianserin pharmacokinetic parameters, which were compared to those from healthy young adults, and to obtain preliminary information regarding the utility of mianserin for the management of hyperkinesis in children. The sample consisted of six prepubescent children wi...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Winsberg BG,Camp-Bruno JA,Vink J,Timmer CJ,Sverd J

    更新日期:1987-06-01 00:00:00

  • Meta-regression analysis of paroxetine clinical trial data: does reporting scale matter?

    abstract:OBJECTIVES:It is unknown to which degree the effect of antidepressant drugs are related to baseline degree of depression, dose level, patient's age, or type of questionnaire used. We explored this for paroxetine. METHODS:We used placebo-controlled published and unpublished randomized, double-blind, clinical trials of ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,meta分析

    doi:10.1097/JCP.0b013e318210bac1

    authors: Klemp M,Tvete IF,Gåsemyr J,Natvig B,Aursnes I

    更新日期:2011-04-01 00:00:00

  • Association study of 27 annotated genes for clozapine pharmacogenetics: validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response.

    abstract:OBJECTIVE:Pharmacogenetic studies on clozapine (CLZ) have provided meaningful insights but have shown redundancies owing to wide interindividual variability and insufficient replication. The present study was designed to validate hitherto suggested candidate genes on CLZ pharmacokinetics and pharmacodynamics and explor...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0b013e31825ac35c

    authors: Lee ST,Ryu S,Kim SR,Kim MJ,Kim S,Kim JW,Lee SY,Hong KS

    更新日期:2012-08-01 00:00:00

  • Idazoxan, an alpha 2 antagonist, augments fluphenazine in schizophrenic patients: a pilot study.

    abstract::Idazoxan, a selective alpha 2-adrenergic antagonist, was added to stable doses of fluphenazine treatment in six patients with schizophrenia who participated in a double-blind, placebo-controlled pharmacologic study. Compared with fluphenazine alone, combining idazoxan (mean dose, 120 mg/day) with fluphenazine (mean do...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Litman RE,Hong WW,Weissman EM,Su TP,Potter WZ,Pickar D

    更新日期:1993-08-01 00:00:00

  • Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance.

    abstract::Twenty-four healthy male and female subjects, who participated in this randomized, double-blind, crossover study, received single nighttime doses of zaleplon 10 mg (therapeutic dose), zaleplon 20 mg, zolpidem 10 mg (therapeutic dose), zolpidem 20 mg, triazolam 0.25 mg (positive control), and placebo. Subjective behavi...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-200006000-00007

    authors: Troy SM,Lucki I,Unruh MA,Cevallos WH,Leister CA,Martin PT,Furlan PM,Mangano R

    更新日期:2000-06-01 00:00:00